Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 536-543

  Würthwein, Gudrun ^a   Young, Charlotte ^a   Lanvers Kaminsky, Claudia ^a   Hempel, Georg ^a,b   Trame, Mirjam N ^a,b   Schwerdtfeger, Rainer ^c   Ostermann, Helmut ^d   Heinz, Werner J ^e   Cornely, Oliver A ^f,g   Kolve, Hedwig ^a   Boos, Joachim ^a   Silling, Gerda ^a   Groll, Andreas H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FEVER; GRAFT RECIPIENT; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 84455172950     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00265-11     Document Type: Article

References (42)

1. Alak A, Moy S, Bekersky I. 1996. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther. Drug Monit. 18:604-609. (Pubitemid 26330484)
2. Ascioglu S, et al. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34:7-14. (Pubitemid 33152659)
3. Bekersky I, et al. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833. (Pubitemid 34157670)
4. Boddy AV, Cole M, Pearson AD, Idle JR. 1995. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother. Pharmacol. 36:53-60.
5. Bow EJ. 2009. Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint. Mycopathologia 168:283-297.
6. Caillot D, et al. 2007. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies-a randomized pilot study (Combistrat trial). Cancer 110: 2740-2746. (Pubitemid 350250344)
7. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
8. Cornely OA, et al. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289-1297.
9. EMEA. 2008. European public assessment report: Cancidas. http://www .ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for -the-public/human/000379/WC500021025.pdf.
10. Food and Drug Administration. 2008. Ambisome (amphotericin B) liposome for injection. FDA label information, Aug. 10, 2008. http://www .accessdata.fda.gov/drugsatfda-docs/label/2008/050740s016lbl.pdf.
11. Food and Drug Administration. 2010. Caspofungin. CANCIDAS. FDA Label information, Oct 2010. http://www.accessdata.fda.gov/drugsatfda -docs/label/2010/021227s028lbl.pdf.
12. Groll AH, Piscitelli SC, Walsh TJ. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44:343-500.
13. Groll AH, et al. 2010. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob. Agents Chemother. 54:4143-4149.
14. Groll AH, Tragiannidis A. 2009. Recent advances in antifungal prevention and treatment. Semin. Hematol. 46:212-229.
15. Groll AH, Walsh TJ. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs 10:1545-1558. (Pubitemid 32717334)
16. Heinemann V, et al. 1997. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob. Agents Chemother. 41:1275-1280. (Pubitemid 27231426)
17. Hempel G, Reinhardt D, Creutzig U, Boos J. 2003. Population pharmacokinetics of liposomal daunorubicin in children. Br. J. Clin. Pharmacol. 56:370-377. (Pubitemid 37188131)
18. Holford NH. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332. (Pubitemid 26177179)
19. Hong Y, et al. 2006. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. 50:935-942. (Pubitemid 43327797)
20. Jonsson EN, Karlsson MO. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
21. Keating, G. M. and B. Jarvis. 2001. Caspofungin. Drugs 61:1121-1129. (Pubitemid 32663869)
22. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. 2011. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput. Methods Programs Biomed. 101: 72-79.
23. Kontoyiannis DP, et al. 2003. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-299. (Pubitemid 36828453)
24. Kuse ER, et al. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet 369:1519-1527.
25. Lindbom L, Pihlgren P, Jonsson N. 2005. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79: 241-257. (Pubitemid 41196689)
26. Maertens J, et al. 2006. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888-2897. (Pubitemid 44937044)
27. Mistry GC, et al. 2007. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J. Clin. Pharmacol. 47:951-961. (Pubitemid 47094100)
28. Mora-Duarte J, et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029. (Pubitemid 35461658)
29. Mosteller RD. 1987. Simplified calculation of body-surface area. N. Engl. J. Med. 317:1098.
30. Nguyen TH, et al. 2007. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J. Antimicrob. Chemother. 60:100-106. (Pubitemid 47073282)
31. Pacetti SA, Gelone SP. 2003. Caspofungin acetate for treatment of invasive fungal infections. Ann. Pharmacother. 37:90-98. (Pubitemid 36068607)
32. Pappas PG, et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45: 883-893. (Pubitemid 47580382)
33. Reed C, et al. 2008. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 47:364-371. (Pubitemid 352009357)
34. Schwartz M, Kline W, Matuszewski B. 1997. Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal. Chim. Acta 351:299-307. (Pubitemid 27522832)
35. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Ibrahim AS. 2009. Recent advances in the management of mucormycosis: from bench to bedside. Clin. Infect. Dis. 48:1743-1751.
36. Stone JA, et al. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46: 739-745. (Pubitemid 34157659)
37. Stone JA, et al. 2004. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. 48:4306-4314. (Pubitemid 39434891)
38. U.S. Department of Health Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. 2001. Guidance for industry-bioanalytical method validation. http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM070107. pdf.
39. Walsh TJ, et al. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49: 4536-4545. (Pubitemid 41552583)
40. Walsh TJ, et al. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402.
41. Walsh TJ, et al. 1998. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:2391-2398. (Pubitemid 28420384)
42. Wuerthein G, et al. 2009. Population Pharmacokinetics of liposomal amphotericin B, caspofungin and the combination of both in allegeneic hematopoietic stem cell recipients. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother, abstr. A1-591.